Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. more
Time Frame | CSTL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.44% | -2.27% | -0.57% |
1-Month Return | -9.21% | -3.96% | 1.21% |
3-Month Return | -7.41% | -9.7% | 7.57% |
6-Month Return | 27.29% | -3.37% | 11.45% |
1-Year Return | 40.49% | 3.71% | 28.48% |
3-Year Return | -28.57% | 3.8% | 29.52% |
5-Year Return | -2.14% | 39.78% | 90.66% |
10-Year Return | 34.91% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 51.87M | 62.65M | 94.08M | 137.04M | 219.79M | [{"date":"2019-12-31","value":23.6,"profit":true},{"date":"2020-12-31","value":28.5,"profit":true},{"date":"2021-12-31","value":42.81,"profit":true},{"date":"2022-12-31","value":62.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 7.31M | 9.69M | 15.82M | 32.01M | 44.98M | [{"date":"2019-12-31","value":16.25,"profit":true},{"date":"2020-12-31","value":21.53,"profit":true},{"date":"2021-12-31","value":35.17,"profit":true},{"date":"2022-12-31","value":71.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 44.55M | 52.96M | 78.26M | 105.03M | 174.81M | [{"date":"2019-12-31","value":25.49,"profit":true},{"date":"2020-12-31","value":30.3,"profit":true},{"date":"2021-12-31","value":44.77,"profit":true},{"date":"2022-12-31","value":60.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 85.91% | 84.54% | 83.18% | 76.64% | 79.53% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.41,"profit":true},{"date":"2021-12-31","value":96.83,"profit":true},{"date":"2022-12-31","value":89.22,"profit":true},{"date":"2023-12-31","value":92.58,"profit":true}] |
Operating Expenses | 37.23M | 59.51M | 118.34M | 196.17M | 242.78M | [{"date":"2019-12-31","value":15.33,"profit":true},{"date":"2020-12-31","value":24.51,"profit":true},{"date":"2021-12-31","value":48.74,"profit":true},{"date":"2022-12-31","value":80.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 4.71M | (6.54M) | (40.08M) | (91.14M) | (67.98M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-138.98,"profit":false},{"date":"2021-12-31","value":-851.48,"profit":false},{"date":"2022-12-31","value":-1936.31,"profit":false},{"date":"2023-12-31","value":-1444.17,"profit":false}] |
Total Non-Operating Income/Expense | (3.62M) | (5.92M) | 134.00K | 7.90M | 20.38M | [{"date":"2019-12-31","value":-17.75,"profit":false},{"date":"2020-12-31","value":-29.05,"profit":false},{"date":"2021-12-31","value":0.66,"profit":true},{"date":"2022-12-31","value":38.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 5.35M | (10.20M) | (40.01M) | (68.90M) | (57.37M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-190.69,"profit":false},{"date":"2021-12-31","value":-748.03,"profit":false},{"date":"2022-12-31","value":-1288.17,"profit":false},{"date":"2023-12-31","value":-1072.44,"profit":false}] |
Income Taxes | 72.00K | 84.00K | (8.72M) | (1.77M) | 101.00K | [{"date":"2019-12-31","value":71.29,"profit":true},{"date":"2020-12-31","value":83.17,"profit":true},{"date":"2021-12-31","value":-8633.66,"profit":false},{"date":"2022-12-31","value":-1748.51,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 5.28M | (10.28M) | (31.29M) | (67.14M) | (57.47M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-194.88,"profit":false},{"date":"2021-12-31","value":-592.99,"profit":false},{"date":"2022-12-31","value":-1272.28,"profit":false},{"date":"2023-12-31","value":-1088.99,"profit":false}] |
Income From Continuous Operations | 5.28M | (10.28M) | (31.29M) | (67.14M) | (75.50M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-194.88,"profit":false},{"date":"2021-12-31","value":-592.99,"profit":false},{"date":"2022-12-31","value":-1272.28,"profit":false},{"date":"2023-12-31","value":-1430.81,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 5.28M | (10.28M) | (31.29M) | (67.14M) | (57.47M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-194.88,"profit":false},{"date":"2021-12-31","value":-592.99,"profit":false},{"date":"2022-12-31","value":-1272.28,"profit":false},{"date":"2023-12-31","value":-1088.99,"profit":false}] |
EPS (Diluted) | (2.11) | (0.56) | (1.23) | (2.58) | (2.16) | [{"date":"2019-12-31","value":-211,"profit":false},{"date":"2020-12-31","value":-56,"profit":false},{"date":"2021-12-31","value":-123,"profit":false},{"date":"2022-12-31","value":-258,"profit":false},{"date":"2023-12-31","value":-216,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CSTL | |
---|---|
Cash Ratio | 6.32 |
Current Ratio | 7.78 |
Quick Ratio | 7.64 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CSTL | |
---|---|
ROA (LTM) | -0.14% |
ROE (LTM) | 1.47% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CSTL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CSTL | |
---|---|
Trailing PE | 137.48 |
Forward PE | NM |
P/S (TTM) | 2.65 |
P/B | 1.83 |
Price/FCF | 49 |
EV/R | 1.78 |
EV/Ebitda | 22.15 |
Castle Biosciences Inc (CSTL) share price today is $28.87
Yes, Indians can buy shares of Castle Biosciences Inc (CSTL) on Vested. To buy Castle Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CSTL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Castle Biosciences Inc (CSTL) via the Vested app. You can start investing in Castle Biosciences Inc (CSTL) with a minimum investment of $1.
You can invest in shares of Castle Biosciences Inc (CSTL) via Vested in three simple steps:
The 52-week high price of Castle Biosciences Inc (CSTL) is $35.84. The 52-week low price of Castle Biosciences Inc (CSTL) is $16.96.
The price-to-earnings (P/E) ratio of Castle Biosciences Inc (CSTL) is 138.6667
The price-to-book (P/B) ratio of Castle Biosciences Inc (CSTL) is 1.83
The dividend yield of Castle Biosciences Inc (CSTL) is 0.00%
The market capitalization of Castle Biosciences Inc (CSTL) is $825.65M
The stock symbol (or ticker) of Castle Biosciences Inc is CSTL